Virtual screening and molecular docking of Anti-Antileishmanial for selected pharmacophore for visceral Leishmaniasis by Rana, Sindhuprava & Sivaperumal, R
Rana et al                                                                                                                Journal of Drug Delivery & Therapeutics. 2018; 8(6-s):230-235 
ISSN: 2250-1177                                                                                  [230]                                                                                 CODEN (USA): JDDTAO 
Available online on 15.12.2018 at http://jddtonline.info 
Journal of Drug Delivery and Therapeutics 
Open Access to Pharmaceutical and Medical Research 
© 2011-18, publisher and licensee JDDT, This is an Open Access article which permits unrestricted 
non-commercial use, provided the original work is properly cited 
Open  Access                                                                                                                                                     Research Article 
Virtual screening and molecular docking of Anti-Antileishmanial for selected 
pharmacophore for visceral Leishmaniasis   
Sindhuprava Rana, R Sivaperumal* 
Department of Biotechnology, Sri Satya Sai University of Technology & Medical Sciences, Sehore-466001 
 
ABSTRACT 
Objective: DNA amplification of Cysteine protease of Leishmania donovani and study the interaction of cysteine protease inhibitors, 
antileishmanial compounds with cysteine protease receptor in various computational programs.  
Materials and methods: Cysteine protease DNA of Leishmania donovani was amplified by PCR. The sequence of cysteine protease has been 
modeled and docked with suitable inhibitors by using various servers and computational tools. The model was designed, compared and 
validated by DOPE and Verify 3D scores. The model and the compound interaction were studied by LibDock and other programs.  
Results: Cysteine protease DNA of Leishmania donovani was successfully amplified by PCR. The structural modeling was done to achieve 
effective enzyme inhibition, inhibitors block the binding sites of that protein. Homology modeling of cysteine protease has been done and docked 
with suitable inhibitors by using various servers and computational tools. The model was designed, compared and validated by DOPE and Verify 
3D scores by using DSv3.5. Licochalcone-a alone showed 37 LibDock conformations with 6 different poses, were suitably docked at the site 1 
with hydrogen bond formation. The study would help to design the novel drugs in respect of resistant one for the treatment of harmful visceral 
Leishmaniasis.  
Conclusion: The molecular interaction of vinyl sulfones, hydrazide derivatives, antileishmanial drugs molecules and carbohydrazide derivatives 
have exhibited ideal molecular interaction with cathepsin B, a cysteine protease of L. donovani, amino acids such as Cys29, Hisl88 and Asn208 
has been found to be active residues. Licochalcone-a and hydrazide derivative may become future antileishmanial compounds, which needs to be 
tested in in vitro and in vivo.  
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INTRODUCTION 
Visceral Leishmaniasis is the most dreaded and destructive 
amongst all the various forms of leishmaniasis. VL is also 
known as Kala- Azar, Black Sickness, Black Fever, Burdwan 
fever, Dumdum fever or Sarkari Bimari etc1-4. VL is the most 
severe form of disease and if left untreated, is usually fatal. 
The parasite is responsible for a spectrum of clinical 
syndromes, which can, in most extreme cases, move from an 
asymptomatic infection to a fatal form (symptomatic) of VL. 
It is well characterized by prolonged fever, splenomegaly, 
hepatomegaly, substantial weight loss, progressive anemia, 
pancytopenia, and hypergammaglobulinemia (mainly IgG 
from polyclonal B cell activation) and is complicated by 
secondary opportunistic infections. The parasite invades and 
multiplies within macrophages (free mononuclear 
phagocytic cells) and affects the reticulo-endothelial system 
including spleen, liver, bone marrow, and lymphoid tissue 5-
10. The outcome of fully developed VL is death, usually said to 
be due to concomitant infection resulting from the weakened 
immunological state of the patient.  
VL is typically caused by L. donovani complex, which includes 
three species: L. donovani donovani, L d. infantum, and L. d. 
chagasi. L. donovani is the causative 12 in the Indian 
subcontinent and East Africa. L. infantum causes VL in the 
Mediterranean basin and L. chagasi is responsible for the 
disease in Central and South America11-14. VL is emerging as 
an important opportunistic infection among people with 
HIV-1 infection. In fact, the parasite may be a cofactor in the 
pathogenesis of HIV infection in human. There are more than 
21 morphologically indistinguishable species of Leishmania 
that infect humans. Conventionally, they are classified and 
named mainly according to their geographical distribution 
and clinical characteristics of the disease where they 
affected15-18.  
The Post kala-azar Dermal Leishmaniasis (PKDL) is a type of 
non ulcerative cutaneous lesion. After recovery from L. 
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donovani infection , VL patients may develop a chronic form 
of cutaneous leishmaniasis i.e., PKDL which is developed in 
about 10% of kala-azar patients generally one or two years 
after the completion of SAG treatment and requires a long 
and expensive treatment. PKDL lesions develop 1- 13 
months post antimony treatment in Sudan, and 1-3 years 
post antimony treatment in India19-20. 
MATERIALS AND METHODS 
Amplification of Leishmania donovani With Gene Specific 
Primers  
PCR is both a thermodynamic and an enzymatic process. 
Successful gradient PCR requires amplification and detection 
under optimal conditions and each reaction component can 
affect the result. The annealing step is critical for high PCR 
specificity. When primers anneal to the template with high 
specificity, this leads to high yields of specific PCR products 
and increases the sensitivity of the amplification reaction. 
However, due to the high primer concentration in the 
reaction, primers will also hybridize to non-complementary 
sequences with mismatches. If the primers anneal to the 
template sequence with low specificity, amplification of 
nonspecific PCR products and primer–dimmers may occur. 
Competition in the amplification reaction between these 
artifacts and the desired PCR product may reduce the yield 
of the specific product, thereby reducing the sensitivity and 
linear range of the real-time reaction.  
A pair of primers was designed based on Leishmania 
donovani cysteine protease (Gen-Bank accession number 
(AF309627). Sequence: forward primer-5′- 
ATGGCGACGTCGAGGGCCGCTCTCTGCGCT-3′ and reverse 
primer 5′- CTACGTGTACTGGCAGGTGTTCATGATCGA -3′. The 
reaction was performed in 30 μL of the solution containing 
24 μg gDNA, 12μl each of forward and reverse primers, 4 mM 
MgCl2, 6μl dNTPs, 12μl PCR buffer, 4μlTaq DNA polymerase, 
and H2O up to 50 μL. PCR amplifi- cation was carried out 
within 94 °C for 3 min, followed by 35 cycles of denaturation 
at 94 °C for 1.0 min, annealing at 48 °C for 1.0 min and 
extension at 72 °C for 1.30 min, and after final extension at 
72 °C for 10 min in a thermal cycler (ABI). 
1).For each 120μl PCR, the following reaction components 
was used. These volumes was multiplied by the number of 
PCR reactions + 5 to make up a single master mix add 24μl to 
the each tube, which can then be dispensed in 120μl 
amounts into numbered, thin-walled PCR tubes: 
Reagent Volume Notes 
H2O 50µl   
10x reaction buffer 12µl   
PCR primer 1 12µl 
[10µM primer stocks = 
1µM final conc.] 
PCR primer 2 12µl   
dNTP mix 6µl [10mM stock] 
Taq polymerase 4µl [5 units/µl stock] 
Template 
Total 
24µl  
120µl 
  
 
2) 6μl of the appropriate template DNA was added to each 
tube. Negative PCR control was set up which consists of 
reaction components and no added template DNA. If you are 
optimizing the PCR, using new template DNA or using a new 
set of primers, it is advisable to also set up positive PCR 
control by including a reaction that contains genomics DNA 
which has been amplified reliably in previous PCRs.  
3) Place the tubes into the thermal cycler and close the lid, 
ensuring that the heated plate inside the lid is in contact with 
the tops of the tubes, by rotating the screw on the top of the 
lid until tight.  
4) Cycling conditions: 
The annealing temperature should be determined for each 
different set of primers, but primers are generally designed 
to have optimal annealing temperatures of 48, 50, 52, 54, 
56,58,60°C (Tm values >60°C).  
Stage Temperature /0C Time /min 
1 94 3min 
2 94 1min 
 64 1min 
 72 1.30min 
3 repeat steps 2, 3 and 4 a further 34 times 
 72 10.0 
 4.0 Forever 
 
5) After cycling, check that amplification was successful by 
running 30μl of each reaction on an agarose gel, with size 
standards. 
Agarose Gel Electrophoresis  
Gel electrophoresis is a widely used technique for the 
analysis of nucleic acids and proteins. Most every molecular 
biology research laboratory routinely uses agarose gel 
electrophoresis for the preparation and analysis of DNA. We 
will be using agarose gel electrophoresis to determine the 
presence and size of PCR products. Electrophoresis is a 
method of separating substances based on the rate of 
movement while under the influence of an electric field. 
Agarose is a polysaccharide purified from sea weed. The 
purpose is to determine the presence or absence of PCR 
products and quantify the size (length of the DNA molecule) 
of the product.  
Materials needed for preparing 1.2% agarose gel: Agarose-
0.6gm, TAE Buffer-50ml, Ethidium bromide-0.2μl, DNA 
ladder standard, Electrophoresis chamber, Power supply, Gel 
casting tray and combs, DNA stain, Staining tray, Gloves, 
Pipette and tips. Add Tris base to ~900 ml H2O. Add acetic 
acid and EDTA to solution and mix. Pour mixture into 1L 
graduated cylinder and add H2O to a total volume of 1L. 
Preparing the Agarose Gel 1.2%  
Measure 0.6g Agarose powder and add it to a 500 ml flask. 
Add 50ml 1xTBE Buffer to the flask. Melt the agarose in a 
microwave until the solution becomes clear. (if using a 
microwave, heat the solution for several short intervals - do 
not let the solution boil for long periods as it may boil out of 
the flask). Let the solution cool to about 50-55°C then add 
Ethidium bromide-0.2μl, swirling the flask occasionally to 
cool evenly. Seal the ends of the casting tray with two layers 
of tape. Place the combs in the gel casting tray. Pour the 
melted agarose solution into the casting tray and let cool 
until it is solid (it should appear milky white). Carefully pull 
out the combs and remove the tape. Place the gel in the 
electrophoresis chamber. Add enough TBE Buffer so that 
there is about 2-3 mm of buffer over the gel.  
Loading the Gel  
2μl of 6X conc. sample loading dye to each 8μl of PCR 
product along with this a controls and ladder was loaded. 
Carefully 10 μl of each sample/ladder mixture loaded into 
separate wells in the gel. The order of each sample loaded on 
the gel was recorded.  
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Running the Gel  
Place the lid on the gel box, connecting the electrodes. The 
electrode wires to the power supply, making sure the 
positive (red) and negative (black) are correctly connected. 
(Remember ―Black (negative) to Red (positive)‖).Turn on 
the power supply to about 100 volts. Maximum allowed 
voltage will vary depending on the size of the 
electrophoresis chamber. Check to make sure the current is 
running through the buffer by looking for bubbles forming 
on each electrode. Check to make sure that the current is 
running in the correct direction by observing the movement 
of the blue loading dye – this will take a couple of minutes (it 
will run in the same direction as the DNA). Let the power run 
until the blue dye approaches the end of the gel. Turn off the 
power. Disconnect the wires from the power supply. Remove 
the lid of the electrophoresis chamber. Using gloves, 
carefully remove the tray and gel.  
Purification of PCR product and sequencing  
The PCR product was purified using PCR product 
purification kit (Qiagen) to remove unused dNTPs, enzyme 
and salt. The ABI Prism BigDye Terminator v1.1 Cycle 
Sequencing ReadyReaction Kit (Applied Biosystems, Foster 
City, CA) was used for the sequencing of the PCR product. 
The sequencing reaction mixture contained 4μL of Big Dye 
premixture, 0.5 x buffers, 3.2 pmol of sequencing primer, and 
approximately 150ng of PCR product template in a total 
volume of 20μL. Sequencing PCR was carried out with the 
same forward primer. PCR amplification was carried out at 
conditions 96°C for 60 sec, followed by 25 cycles of 
denaturation at 96°C for 10sec, annealing at 50°C for 05sec 
and extension at 60°C for 4 min in a thermal cycler (ABI).  
The product was processed, dried and resuspended in 19μl 
formamide and then loaded in ABI 3130xL genetic analyzer 
for sequencing following the manufacturer‘s 
recommendations. The sequencing results were analyzed 
with Sequencer software under the condition of signal/noise 
> 98%. 
RESULTS AND DISCUSSION 
Sequence retrieval, alignment and template selection 
The amino acid sequence of cysteine protease with NCBI id 
AAL09444 was retrieved from NCBI, the protein database of 
the National Center for Biotechnology Information 
(www.ncbi.nlm.nih.gov/). A BLASTP search was performed 
against the Protein Data Bank (PDB)  to identify a suitable 
template for homology modeling. Generally, the quality of a 
template increases with its overall sequence identity and 
decreases with the increasing number and length of gaps in 
the alignment. The PDB structure of 1PPP chain A was 
selected as the best template based on the amino acid 
identities, the lengths of the gaps and the E-value. 
Template Selection 
Template selection for homology modeling, best one target 
templates are selected based on the Sequence identify to the 
target protein, resolution and completeness of the structure 
(figure 1 A B C). The template (PDB ID:1AimA) with 58.8% 
structural identity as shown in the following table  which is 
the crystallographic structure of a cysteine protease 
(cathepsin L) in Trypanosoma cruzi showed highest 
similarity to most of the target proteases. The structure had 
sequence identity 58.8% similarity to target sequence 
coverage by template structure proteases relatively high 
resolution of 2.00Å. The template had fairly-good sequence 
coverage of the target proteases; however it was incomplete 
in the N-terminal domain associated with an inactive 
peptidase or zymogen. Removal of the N-terminal inhibitor 
domain either by interaction with a second peptidase or by 
autocatalytic cleavage activates the zymogen. 
 
Target Template Model 
residues 
range 
Sequence id E-value 
QMEAN4-Z 
score Accession 
No 
Sequence 
lengths 
PDB ID Lengths 
AAL09444.1  
PDB 
ID:1AimA 
 126-341 15824693 9.99e-94 -2.08 
 
The template structural identity as shown in the above target template value was predicted from Swiss Automated Model 
programs superfamily sequence search program. 
 
Figure 1: Predicted homology models of cysteine protease  from Leishmania donovani varieties; A is a The structure of cysteine 
protease enzyme, B Receptor -ligand molecule, C. Groove binder, The protein model that was carried out using homology 
modeling SWISS model software 
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Template-Target Alignment 
The 3D structures of Leishmania donovani cysteine proteases 
were built and refined using Swiss model and structure were 
further validate check its structure quality. Based on this 
assessment of the structure loop refinements were 
performed to improve the model quality. The summary 
indicates the model QMEAN4 Z-score (-2.08) energy scores 
calculated by Swiss model and some of the scores of model 
validation that are discussed in greater detail ahead. 
The identity best template (PDB-1aimA) was good quality 
having (216) residues found to have residues in most 
favored region and allowed regions 98.9%. The Swiss model 
indicated the templates as having acceptable 
stereochemistry; the secondary structures classifications 
two type SCOP alpha helix (magenta) and beta strand 
(yellow) and turn residues (blue) in remaining residues 
random (white) part of this PDB chain in the (domain red) 
SCOP tail (violet): domain residues (1-382) are colored by 
quality to enhance visualization of errors [31]. Blue 
represents highly scored residues and red poorly scored 
residues that are likely to be erroneous. This infers that the 
structures are of enough good quality to be used for 
modeling. The sub site region of these structures occurs 
between the left and right lobe and is mostly blue indicating 
high scoring residues in this region. The conserved domain 
structure is also of good quality with an exception of its N-
terminal, where there is a 1-turn α-helix that is colored red. 
This C-terminal helix region however doesn’t directly 
overlay the active site and may not be employed in the study 
of protease inhibition. Given the CATH domain id (1aimA00) 
FunFams papain like domain (Red 3, 1, 1). CP domain (Green 
3, 90, 70, 10) higher (>95%) lower level domain (<35%) for 
the templates respectively, Modeling allowed us to realize 
locally stressed regions of template (that is local regions of 
the template that had high energy values). Swiss automated 
model was used to assess the stereochemistry of the 
templates and the results are shown in (Figure 2: A, B). 
 
 
Figure 2: stereochemistry of the templates 
  
Virtual Screening 
Active site identification in the target protein is the starting 
point for virtual screening. Using was metaPocket 2.0 server. 
Identification ligand binding site in 3D structure of the 
cysteine protease. Three pockets were located in the target, 
and based on further analysis of amino acid residues 
involved in the active site. Become it having 13 residues in 
which Asn26, Gln237, Asp85, His86, His181 and His209 have 
been reported to be conserved in the active site of cysteine 
protease. Two components searching and scoring are 
involved in most of the docking algorithms. The vina scoring 
function amalgamates knowledge based potentials and 
empirical scoring functions, which extracts empirical 
information from both the conformational preferences of the 
receptor-ligand complexes and the experimental affinity 
measurements. The three-dimensional of all the anti-
Leishmanial drugs and medicinal cysteine protease were 
screened from PubChem and Drug Bank databases were 
screened with inhibitor designs drugs and compounds and 
were selected for internal and comparative study. Using the 
ligdock program, schematic diagrams of protein-ligand 
interactions for top four receptor-ligand docked complexes 
were generated in 3D space. It represents the hydrogen and 
hydrophobic interactions between ligand and active site 
residues of the cysteine protease. The molecule was 
interacting with Ser309 Lys 307 and residue through 
hydrogen bond at a distance of 3.01 Å and 2.97 Å 
respectively while Ser154, Leu291, Val141, Pro140, Glu175, 
Val156, Lys142, His288, Phe153 & Gly151, 289, Thr139, 
Glu160 residues were involved in hydrophobic interactions. 
Molecular docking studies 
Docking studies were carried out by using the program 
discovery studio 2.5. Total docking score 8.338 ligand 
interactions. This program starts with a ligand molecule in 
an arbitrary conformation, orientation and position and 
finds favorable dockings in a protein binding site using both 
simulating annealing and genetic algorithms. The program 
discovery studio software Tools (DS v2.5), Molecular Viewer, 
was used to prepare the protein and the ligands. For the 
macromolecule the 3D crystal structure of CP (PDB ID: 
1aimA), resolved at 2.0 Å, was chosen as the docking pattern 
from the Protein Data Bank. Earlier than docking studies, the 
macromolecular structure was modified to get more logical 
and precise outcomes. The A, and D chains were kept 
whereas the H, X, and Y chains were unmerged and deleted 
because the hexamer was symmetrical. There are two active 
sites in this macromolecule. The existed ligands in the crystal 
were all omitted so that other molecules could be docked 
and also crystallographic water molecules in the structure 
were eliminated. Polar hydrogen’s were added, and then 
A B 
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Kollman United Atom charges and atomic salvation 
parameters were assigned. The grid maps of docking studies 
were computed using the discovery studio included in the 
discovery studio 2.5.distribution.  
Estimated free energy charge of binding = sum of final 
intermolecular energy and torsion free energy of ligand. 
         
Figure 3: Amino acids exhibited interaction with ligand(4-Hydroxynonenal)  are Glu175, Val156, Lys142, His288, Gly157, 
Thr139, Phe153, Gly289, Ser309, Cys150, Asn308, Val290, Ser154, Lys307, Leu291, Val141 and Pro140 of model protein of 
cystein protenase of Leishmania donovani in the docking score 8.338  GOLD. CID: 5283344 (4-Hydroxynonenal, or 4-hydroxy-2-
nonenal or 4-HNE or HNE) is an α, β-unsaturated hydroxyalkenal that is produced by lipid peroxidation in cells. 
 
Pharmacophore and 3D QSAR 
The constructed model was tested for its predictive power 
with a test set of 29 molecules. Based upon a PLS factor of 
five, statistical significance of the model was achieved for 
useful structural insights. Pharmacophore is an important 
and unifying concept in rational drug design that embodies 
the notion that molecules are active at a particular enzyme 
or receptor because they possess a number of chemical 
features that favorably interact with the target and which 
possess geometry complementary to it. A pharmacophore 
hypothesis collects common features distributed in three-
dimensional space representing groups in a molecule that 
participate in important interactions between drug and 
active site. Rapid development of combinatorial chemistry 
and high throughput screening methods in recent years has 
significantly increased a bulk of experimental structure–
activity relationship (SAR) datasets. These developments 
have emphasized a need for reliable analytical methods for 
biological SAR data examination such as quantitative SAR 
(QSAR). QSAR, a CAMD (Computer Aided Molecular Design) 
technique has been traditionally perceived as a means of 
establishing correlations between trends in chemical 
structure modifications and respective changes of biological 
activity. 
The computational analysis using both software and servers 
of the modeled protein structure enable us the biological 
properties. The cysteine protease of L. donovani, with the 
hypothetical protein modeled that was prepared and 
retrieved from Swiss model tool. 
 
Modeled Structure prediction using homology modeling 
approaches:  
The proper template identification after pBLAST, followed by 
modeled protein quality assessment enables to understand 
the suitable functions, and localization of the subcellular 
protein and their interaction with ligands. The most common 
and approximate prediction method is homology modeling 
that provides a proper idea about the protein. The homology 
model of cysteine protease is shown in figure 4. The figure 
labeled as sequence alpha (α), beta (β) and flexible loops 
(FL). The cysteine protease consists of seven alpha helixes, 
ten beta sheet, three ƞ (small helixes) and few flexible loops. 
The secondary sequence was clearly mentioned the actual 
amino acids residues involved in making alpha helixes, beta 
sheet, flexible loops and small helixes (with three amino 
acids residues). All the models which were designed from 
the different servers were compared and validated by DOPE 
scores by using DSv3.5. The suitable template model that 
retrieved from the Swiss model has been taken for our study 
which has the lowest DOPE value of -43031.174938 as the 
best-modeled structure. The model structure was proved by 
Verify 3D that showed 83.06 % value. The protein verify by 
using DSv3.5, shows the 111.74 verify score which lies in 
between verify expected high score (139.723) and verify 
expected low score (62.8754). The model validation 
PROCHECK tool was used to determine Ramachandran plot 
that assures the quality model. The result of Ramachandran 
plot showed the amount of amino acid residues i.e. 85% 
favored regions, 13.1% additional allowed regions, 1.5% 
generously allowed regions and 0.4% disallowed regions 
favored represented as a reliable and good quality model. 
The reliability of the modeled protein was also checked by 
using ERRAT that showed 83.162 overall model quality. 
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Figure 4: Ligand prtein interaction of Licochalcone with CP model 
CONCLUSION 
As drug resistance problem persists in case of Leishmaniasis, 
Cathepsin like cysteine protease is an important target 
protein for the identification of novel lead compound of 
Leishmaniasis. Cathepsin like cysteine protease representing 
a major component of the proteolytic repertoire and play an 
important role in intracellular protein degradation. Cysteine 
protease also required for parasite replication and virulence. 
A three dimensional structure of Cathepsin L like cysteine 
protease (cpL) and Cathepsin B like cysteine protease (cpB) of 
the Leishmania donovani was constructed through homology 
modeling using X-ray crystal structure of bovine cathepsin B 
(PDB ID: l QDQ) and recombinant rat cathepsin B (PDB ID: 1 
CPJ) for the Cathepsin B like cysteine protease and X-ray 
crystal structure of cruzain (PDB ID: 1 AIM) for the Cathepsin 
L like cysteine protease. The homology modeling was done by 
using Modeller 9v5 and discovery studio software. The final 
model obtained by the molecular mechanics and dynamics 
method was assessed by PROCHEK & VERIFY 3-D graph, 
which showed that the final model is reliable. The model 
active site of Cathepsin B was used for the virtual high 
throughput screening of around hundred compounds (vinyl 
sulfones, hydrazides derivatives anti leishmanial drugs 
molecules, carbohydrazide derivatives) for the potential 
cysteine protease inhibitors, using AutoDock v4.l, GOLDv2.l. 
Based on high simulation docking score and fitness value, 
different sixteen compounds were selected. Out of these 13 
have better fitness score and hydrogen bond. These may act 
as a potential drug for Cathepsin like cysteine protease of 
Leishmania donovani in future. 
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